Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk

A meta-analysis

Theodoros N. Sergentanis, Konstantinos P. Economopoulos, Souzana Choussein, Nikos F. Vlahos

    Research output: Contribution to journalArticle

    Abstract

    Introduction: This meta-analysis aims to examine whether the genotype status of Msp1, Ile462Val, and Thr461Asn polymorphisms in cytochrome P450 1A1 (CYP1A1) is associated with endometrial cancer risk. Methods: Eligible case-control studies were identified through search in MEDLINE (end of search: August 2010). Pooled odds ratios (ORs) were appropriately derived from fixedeffects or random-effects models. Results: Concerning MspI polymorphism, 8 studies were eligible (1456 cases and 2371 controls); 9 studies were eligible (1889 cases and 3662 controls) for Ile462Val and 6 studies were eligible (1272 cases and 2122 controls) for Thr461Asn. MspI polymorphism was not associated with endometrial cancer risk (for heterozygous TC vs TT carriers: OR = 0.83, 95% confidence interval [CI], 0.59-1.15, random effects; for homozygous CC vs TT carriers: OR = 1.00, 95% CI, 0.55-1.82, fixed effects). Similarly, Ile462Val polymorphism was not associated with endometrial cancer risk (for heterozygous Ile/Val vs Ile/Ile carriers: OR = 1.27, 95% CI, 0.78-2.06, random effects; for homozygous Val/Val vs Ile/Ile carriers: OR = 1.16, 95% CI, 0.48-2.81, fixed effects). Accordingly, Thr461Asn status was not significantly associated with endometrialcancer risk. The same results were reproduced in Caucasians. Conclusions: The 3 examined CYP1A1 genotype polymorphisms do not seem to confer any additional risk for endometrial cancer in Caucasians. Accumulation of further data seems mandatory for future race-specific analyses.

    Original languageEnglish (US)
    Pages (from-to)323-331
    Number of pages9
    JournalInternational Journal of Gynecological Cancer
    Volume21
    Issue number2
    DOIs
    StatePublished - Feb 2011

    Fingerprint

    Endometrial Neoplasms
    Cytochrome P-450 Enzyme System
    Meta-Analysis
    Odds Ratio
    Confidence Intervals
    Genes
    Genotype
    MEDLINE
    Case-Control Studies

    Keywords

    • Cytochrome P450 1A1
    • Endometrial cancer
    • Ile462Val polymorphism
    • MspI polymorphism
    • Thr461Asn polymorphism

    ASJC Scopus subject areas

    • Obstetrics and Gynecology
    • Oncology

    Cite this

    Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk : A meta-analysis. / Sergentanis, Theodoros N.; Economopoulos, Konstantinos P.; Choussein, Souzana; Vlahos, Nikos F.

    In: International Journal of Gynecological Cancer, Vol. 21, No. 2, 02.2011, p. 323-331.

    Research output: Contribution to journalArticle

    Sergentanis, Theodoros N. ; Economopoulos, Konstantinos P. ; Choussein, Souzana ; Vlahos, Nikos F. / Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk : A meta-analysis. In: International Journal of Gynecological Cancer. 2011 ; Vol. 21, No. 2. pp. 323-331.
    @article{73f921d2f1f649b487dbff15d99ecee6,
    title = "Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: A meta-analysis",
    abstract = "Introduction: This meta-analysis aims to examine whether the genotype status of Msp1, Ile462Val, and Thr461Asn polymorphisms in cytochrome P450 1A1 (CYP1A1) is associated with endometrial cancer risk. Methods: Eligible case-control studies were identified through search in MEDLINE (end of search: August 2010). Pooled odds ratios (ORs) were appropriately derived from fixedeffects or random-effects models. Results: Concerning MspI polymorphism, 8 studies were eligible (1456 cases and 2371 controls); 9 studies were eligible (1889 cases and 3662 controls) for Ile462Val and 6 studies were eligible (1272 cases and 2122 controls) for Thr461Asn. MspI polymorphism was not associated with endometrial cancer risk (for heterozygous TC vs TT carriers: OR = 0.83, 95{\%} confidence interval [CI], 0.59-1.15, random effects; for homozygous CC vs TT carriers: OR = 1.00, 95{\%} CI, 0.55-1.82, fixed effects). Similarly, Ile462Val polymorphism was not associated with endometrial cancer risk (for heterozygous Ile/Val vs Ile/Ile carriers: OR = 1.27, 95{\%} CI, 0.78-2.06, random effects; for homozygous Val/Val vs Ile/Ile carriers: OR = 1.16, 95{\%} CI, 0.48-2.81, fixed effects). Accordingly, Thr461Asn status was not significantly associated with endometrialcancer risk. The same results were reproduced in Caucasians. Conclusions: The 3 examined CYP1A1 genotype polymorphisms do not seem to confer any additional risk for endometrial cancer in Caucasians. Accumulation of further data seems mandatory for future race-specific analyses.",
    keywords = "Cytochrome P450 1A1, Endometrial cancer, Ile462Val polymorphism, MspI polymorphism, Thr461Asn polymorphism",
    author = "Sergentanis, {Theodoros N.} and Economopoulos, {Konstantinos P.} and Souzana Choussein and Vlahos, {Nikos F.}",
    year = "2011",
    month = "2",
    doi = "10.1097/IGC.0b013e31820575c0",
    language = "English (US)",
    volume = "21",
    pages = "323--331",
    journal = "International Journal of Gynecological Cancer",
    issn = "1048-891X",
    publisher = "Lippincott Williams and Wilkins",
    number = "2",

    }

    TY - JOUR

    T1 - Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk

    T2 - A meta-analysis

    AU - Sergentanis, Theodoros N.

    AU - Economopoulos, Konstantinos P.

    AU - Choussein, Souzana

    AU - Vlahos, Nikos F.

    PY - 2011/2

    Y1 - 2011/2

    N2 - Introduction: This meta-analysis aims to examine whether the genotype status of Msp1, Ile462Val, and Thr461Asn polymorphisms in cytochrome P450 1A1 (CYP1A1) is associated with endometrial cancer risk. Methods: Eligible case-control studies were identified through search in MEDLINE (end of search: August 2010). Pooled odds ratios (ORs) were appropriately derived from fixedeffects or random-effects models. Results: Concerning MspI polymorphism, 8 studies were eligible (1456 cases and 2371 controls); 9 studies were eligible (1889 cases and 3662 controls) for Ile462Val and 6 studies were eligible (1272 cases and 2122 controls) for Thr461Asn. MspI polymorphism was not associated with endometrial cancer risk (for heterozygous TC vs TT carriers: OR = 0.83, 95% confidence interval [CI], 0.59-1.15, random effects; for homozygous CC vs TT carriers: OR = 1.00, 95% CI, 0.55-1.82, fixed effects). Similarly, Ile462Val polymorphism was not associated with endometrial cancer risk (for heterozygous Ile/Val vs Ile/Ile carriers: OR = 1.27, 95% CI, 0.78-2.06, random effects; for homozygous Val/Val vs Ile/Ile carriers: OR = 1.16, 95% CI, 0.48-2.81, fixed effects). Accordingly, Thr461Asn status was not significantly associated with endometrialcancer risk. The same results were reproduced in Caucasians. Conclusions: The 3 examined CYP1A1 genotype polymorphisms do not seem to confer any additional risk for endometrial cancer in Caucasians. Accumulation of further data seems mandatory for future race-specific analyses.

    AB - Introduction: This meta-analysis aims to examine whether the genotype status of Msp1, Ile462Val, and Thr461Asn polymorphisms in cytochrome P450 1A1 (CYP1A1) is associated with endometrial cancer risk. Methods: Eligible case-control studies were identified through search in MEDLINE (end of search: August 2010). Pooled odds ratios (ORs) were appropriately derived from fixedeffects or random-effects models. Results: Concerning MspI polymorphism, 8 studies were eligible (1456 cases and 2371 controls); 9 studies were eligible (1889 cases and 3662 controls) for Ile462Val and 6 studies were eligible (1272 cases and 2122 controls) for Thr461Asn. MspI polymorphism was not associated with endometrial cancer risk (for heterozygous TC vs TT carriers: OR = 0.83, 95% confidence interval [CI], 0.59-1.15, random effects; for homozygous CC vs TT carriers: OR = 1.00, 95% CI, 0.55-1.82, fixed effects). Similarly, Ile462Val polymorphism was not associated with endometrial cancer risk (for heterozygous Ile/Val vs Ile/Ile carriers: OR = 1.27, 95% CI, 0.78-2.06, random effects; for homozygous Val/Val vs Ile/Ile carriers: OR = 1.16, 95% CI, 0.48-2.81, fixed effects). Accordingly, Thr461Asn status was not significantly associated with endometrialcancer risk. The same results were reproduced in Caucasians. Conclusions: The 3 examined CYP1A1 genotype polymorphisms do not seem to confer any additional risk for endometrial cancer in Caucasians. Accumulation of further data seems mandatory for future race-specific analyses.

    KW - Cytochrome P450 1A1

    KW - Endometrial cancer

    KW - Ile462Val polymorphism

    KW - MspI polymorphism

    KW - Thr461Asn polymorphism

    UR - http://www.scopus.com/inward/record.url?scp=79956150209&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79956150209&partnerID=8YFLogxK

    U2 - 10.1097/IGC.0b013e31820575c0

    DO - 10.1097/IGC.0b013e31820575c0

    M3 - Article

    VL - 21

    SP - 323

    EP - 331

    JO - International Journal of Gynecological Cancer

    JF - International Journal of Gynecological Cancer

    SN - 1048-891X

    IS - 2

    ER -